Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular AMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT06178770
What this trial is testing

Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 414
Not applicableStudy completedNCT06021366
What this trial is testing

Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 2,089
Large-scale testing (Phase 3)UnknownNCT00370539
What this trial is testing

Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
Shahid Beheshti University of Medical Sciences
Large-scale testing (Phase 3)Study completedNCT02157077
What this trial is testing

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

Who this might be right for
Macular DegenerationWet Macular DegenerationRetinal Degeneration+2 more
Centre Hospitalier Intercommunal Creteil 90
Testing effectiveness (Phase 2)Ended earlyNCT00347165
What this trial is testing

Intravitreal Bevacizumab for Age-Related Macular Degeneration

Who this might be right for
Age Related Macular Degeneration
Asociación para Evitar la Ceguera en México 50
Early research (Phase 1)Active Not RecruitingNCT05657301
What this trial is testing

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration
Chengdu Origen Biotechnology Co., Ltd. 25
Post-approval studies (Phase 4)UnknownNCT01670162
What this trial is testing

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

Who this might be right for
Age Related Macular DegenerationPigment Epithelial Detachment
Tennessee Retina 30
Not applicableStudy completedNCT04543331
What this trial is testing

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)
Novartis Pharmaceuticals 572
Not applicableStudy completedNCT05037396
What this trial is testing

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 9,457
Not applicableStudy completedNCT01027468
What this trial is testing

Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Medical University of Vienna 160
Testing effectiveness (Phase 2)Study completedNCT00607750
What this trial is testing

Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

Who this might be right for
Age-Related Macular Degeneration
CoMentis 60
Testing effectiveness (Phase 2)Study completedNCT05637255
What this trial is testing

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Who this might be right for
Wet Macular DegenerationNeovascular Age-related Macular DegenerationMacular Degeneration
Sylentis, S.A. 99
Not applicableEnded earlyNCT02005133
What this trial is testing

A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

Who this might be right for
Wet Age-related Macular Degeneration
Novartis Pharmaceuticals 188
Post-approval studies (Phase 4)Not Yet RecruitingNCT07365371
What this trial is testing

A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

Who this might be right for
Polypoidal Choroidal Vasculopathy (PCV)Neovascular Age Related Macular Degeneration (AMD)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 174
Testing effectiveness (Phase 2)Active Not RecruitingNCT05230537
What this trial is testing

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration
Novartis Pharmaceuticals 168
Early research (Phase 1)Not Yet RecruitingNCT07764965
What this trial is testing

Evaluation of PAN-90806 Eye Drops in Healthy Subjects

Who this might be right for
Wet Age Related Macular DegenerationNeovascular (Wet) Age-Related Macular Degeneration
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. 20
Large-scale testing (Phase 3)Study completedNCT04264819
What this trial is testing

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 295
Testing effectiveness (Phase 2)Enrolling By InvitationNCT03999801
What this trial is testing

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular Degeneration
AbbVie 865
Testing effectiveness (Phase 2)Active Not RecruitingNCT05387837
What this trial is testing

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

Who this might be right for
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Ashvattha Therapeutics, Inc. 50
Testing effectiveness (Phase 2)Study completedNCT00320788
What this trial is testing

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Regeneron Pharmaceuticals 159
Next Page